[Radiation therapy of malignant eyelid tumors].
The authors presented the short- and long-term results of brachytherapy and combined radiotherapy in 348 patients with malignant eyelid neoplasms localized in the lower eyelid in 187 patients, in the upper eyelid in 99, in both eyelids in 4, in the inner angle of the eye in 39 and in the outer angle of the eye in 10 patients. A single focal dose was 1.5-2.5 Gy, a total dose 45-80 Gy with relation to tumor prevalence and histological structure. The eyeball was protected with the help of a lead lens ("eye prosthesis") and a universal tungsten membrane. The devices ensured nearly 100% protection of the eyelid against ionizing radiation. Direct clinical cure was noted in 342 patients, partial tumor resorption in 6 patients. Three-year recurrence-free survival was noted in 330 patients (94.8%), five-year survival in 319 (92.8%).
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy*; D002280:Basal Cell Carcinoma / Q000401:mortality / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy*; D002908:Chronic Disease; D005142:Eyelid Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D005720:Gamma Rays / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000532:radiotherapy*; D008722:Methods; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011832:Radiation Injuries / Q000453:epidemiology; D011879:Radiotherapy Dosage
Luchevaia terapiia zlokachestvennykh opukholeĭ vek.